Healthcare Industry News: drug-eluting balloon
News Release - September 21, 2009
Invatec Announces Launch of REEF HP PTA Balloon Catheter in EuropeNew Catheter Specifically Designed for AV Shunts and Hard-to-Dilate Peripheral Lesions
LISBON, Portugal, Sept. 21--(HSMN NewsFeed)--Invatec, a comprehensive innovator of interventional products, today announced the availability of REEF HP(TM), a PTA Balloon Catheter, ideal for use in all peripheral high pressure dilatation procedures. The “lesion-specific” design of the balloon material is particularly useful in “hard-to-dilate” situations and the availability of variable shaft lengths mean that the Reef HP is equally suited to both arteriovenous (AV) shunts (50cm shaft),and peripheral applications (80/120cm shaft).
”The REEF HP is a robust and highly stable balloon, capable of counter-acting even the most severe arterial lesions, with minimal slippage and a high pressure threshold,“ commented Stefan Widensohler and Andrea Venturelli, co-founders of Invatec.”It has a “lesion-specific” design that is ideal for use in dialysis patients whose AV shunts often create short, fibrous, and hard-to-dilate lesions where the shunt is connected to the native vessel.
The REEF HP balloon is made from Invatec’s proprietary FLEXITEC(TM) XF, an extremely durable material with a large working pressure range of up to 22 bar, offering complete control during high pressure procedures. It is also a low compliant balloon, offering a uniform dilatation force and strong shape retention to dilate resistive lesions with greater success and extreme stability.
Headquartered in Italy and with manufacturing in Italy and Switzerland, Invatec is one of the world’s fastest growing companies in the design, development and production of interventional cardiology and peripheral vascular products for the treatment of coronary and peripheral arterial disease. Driven by research and technology, Invatec actively collaborates with physicians and centres of excellence to develop products that will improve life expectancy and quality of life for patients. Vertically integrated, Invatec also has the in-house ability to design, develop, manufacture and assemble its entire product offering from raw materials. As a result, the company has one of the largest therapeutic catheter product lines in the world, including 9 stent platforms, 6 angioplasty balloon platforms, 3 drug-eluting balloon platforms and accessory devices, now sold in over 70 countries.
Dedicated to "making ideas come alive," the company was founded in 1996 by Andrea Venturelli and Stefan Widensohler, and has grown to almost 1,000 employees. For more information, visit www.invatec.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.